Intraocular iontophoretic device and associated methods

• US 20070106278A1
• Filed: 04/27/2006
• Published: 05/10/2007
• Est. Priority Date: 10/24/2005
• Status: Active Grant

• Current Assignee: Aciont, Inc.
• Original Assignee: Aciont, Inc.
• Inventors: Higuchi, John, Li, S.
• Granted Patent: US 8,755,880 B2
• Time in Patent Office: Days
• US Class Current: 604/891.100
• CPC Class Codes: A61N 1/044 Shape of the electrode
• CPC Class Codes: A61N 1/0448 Drug reservoir
• CPC Class Codes: A61N 1/306 Arrangements where at least part of the apparatus is introduced into the body

Abstract

The present invention includes methods and devices for delivering an active agent into the eye of a subject. One such device may include an anode assembly having an anode housing and an anode configured to electrically couple to a power source, the anode assembly being configured to contact and remain against a surface of the eye. The device may also include a cathode assembly having a cathode housing and a cathode configured to electrically couple to the power source, the cathode assembly being configured to contact and remain against the surface of the eye. Additionally, the device may include at least one active agent reservoir functionally associated with at least one of the anode assembly and the cathode assembly.

Claims

1. A self-contained device for delivering an active agent into an eye of a subject, comprising:

a device housing;

a first electrode assembly located at least partially within the housing and having a first electrode and a reservoir configured to contain the active agent, said first electrode assembly configured to contact and remain against a surface of the eye for a sufficient amount of time to deliver the active agent to the eye;

a second electrode assembly located at least partially within the housing and having a second electrode configured to be opposite in polarity from the first electrode; and

a power source located at least partially within the housing and electrically coupled to the first electrode and to the second electrode.

2. The device of claim 1, wherein the first electrode assembly and the second electrode assembly are located substantially within the device housing.

3. The device of claim 1, wherein the second electrode assembly includes a reservoir configured to contain a secondary compound.

4. The device of claim 1, further comprising a barrier element associated with the device housing and located between the first electrode assembly and the second electrode assembly, the barrier element being configured to electrically isolate the first electrode from the second electrode at the surface of the eye.

5. The device of claim 4, wherein the barrier element at least substantially surrounds each of the first electrode assembly and the second electrode assembly at the surface of the eye to preclude the passage of fluid and minimize current flow between the first electrode assembly and the second electrode assembly.

6. The device of claim 5, wherein the barrier element is configured to depressurize a space between the surface of the eye and at least a portion of the barrier element in order to maintain a position of the device.

7. The device of claim 4, wherein the barrier element is continuous with the device housing.

8. The device of claim 1, wherein the device housing is configured to depressurize a space between the surface of the eye and at least a portion of the device housing in order to maintain a position of the device.

9. The device of claim 8, wherein the device housing further includes a suction element configured to cause depressurization.

10. The device of claim 1, wherein the device housing is configured to allow eyelids to close substantially completely thereover.

11. The device of claim 10, wherein the device housing is a contact lens.

12. The device of claim 10, wherein the device housing is a scleral lens.

13. The device of claim 1, further comprising a handle configured to assist manipulation of the device.

14. The device of claim 1, wherein the power source is enclosed substantially within the device housing.

15. The device of claim 1, wherein all conductive connections between the power source and both the first electrode and the second electrode are enclosed substantially within the device housing.

16. The device of claim 1, further including microelectronics located within the device housing to control delivery of the active agent.

17. The device of claim 1, wherein the second electrode is oriented within the device housing to face the surface of the eye.

18. The device of claim 1, wherein the second electrode is oriented within the device housing to face away from the surface of the eye.

19. The device of claim 1, wherein the second electrode assembly is in contact with the surface of the eye.

20. The device of claim 1, wherein the second electrode is a return electrode.

21. A method of controlling delivery of an active agent to a localized area in an eye of a subject, comprising:

positioning the device of claim 1 on an eye surface, said device having an inter-electrode distance between the first electrode assembly and the second electrode assembly that controls depth and extent of penetration of the active agent within the eye; and

iontophoretically delivering the active agent in the eye with at least the first electrode assembly.

22. The method of claim 21, wherein the active agent provides an immediate therapeutic effect.

23. The method of claim 21, wherein the active agent provides a sustained therapeutic effect.

24. The method of claim 21, wherein the active agent provides an immediate therapeutic effect and a sustained therapeutic effect.